Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Kiniksa Pharmaceuticals International, plc

35 indications, side-by-side phase, drug & LoA

$51.89

+0.31 (+0.6%)

C 47Pipeline Score Overvalued Pharma · Commercial
Market Cap
4.10 B
EPS
0.97
P/E Ratio
58.67 $
Value Trade
23.72 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    214.27 M

  • R&D Expenses

    27.48 M

  • Operating CF

    50.20 M

  • Total Assets

    825.28 M

  • Total Liabilities

    219.59 M

  • Equity

    605.69 M

  • D/E Ratio

    12,345

-8.21 %
Week
24.28 %
1 Month
12.18 %
3 Month
29.16 %
6 Month
265.66 %
5 Year
117.75 %
All Time
Cash Data
Profitable

  • Cash Position

    468.09 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Apr 28, 2026
Overview
Volume
362.76 K
52 Week Range
26.27 - 59.87
% held by Insiders
43.67 %
% held by Institutions
59.45 %
Enterprise Value
3.64 B
Total Shares
46.20 M
Short %
7.02 %
Float Shares
38.90 M
Company Description
HQ: 105 PICCADILLY, SECOND FLOOR, ...
Employees:366
https://www.kiniksa.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
"Phase 2 data readout" example
KPL-387 Recurrent pericarditis
Phase 2
—
Biologics
Cardiovascular System
KPL-387 Recurrent pericarditis
Phase 2
—
Biologics
Cardiovascular System
KPL-387 Recurrent pericarditis
Phase 2
—
Biologics
Cardiovascular System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C47
Pipeline Score
$1.1B
Pipeline Value
Overvalued
Valuation Signal
7
Drugs Scored
0.3x
rNPV / MCap
Top 66%
Small Cap
(rank 309 of 905)
Percentile Rank
Kiniksa Pharmaceuticals International, plc carries a moderate pipeline score (47/100), with $1.6B risk-adjusted pipeline value, led by Mavrilimumab in COVID-19 (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
mavrilimumab
Small molecule		COVIDPhase 2NCT0444746940% $1.0B COMPLETED 814 - -Jan 14, 2022 -Jan 22, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
KPL-387
recurrent pericarditis
Phase 2/3
2025-07-30
KPL-387
recurrent pericarditis
Phase 2/3
2025-07-30
KPL-387
recurrent pericarditis
Phase 2/3
2025-07-30
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in KNSA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
KNSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KNSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KNSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
KNSA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
KNSA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Kiniksa Pharmaceuticals International, plc (KNSA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How KNSA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Valvular Heart Disease #2 of 13 PHASE 2 KPL-387
NVS ABT ·dev EW ·dev
 $14.89B 0.86 CONTENDER
Cardiovascular Disorders #3 of 12 PHASE 2 KPL-387
AZN BBIO ABT ·dev
 $150.0B 0.84 CONTENDER